Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OLARATUMAB Cause Malignant neoplasm progression? 43 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 43 reports of Malignant neoplasm progression have been filed in association with OLARATUMAB. This represents 7.6% of all adverse event reports for OLARATUMAB.

43
Reports of Malignant neoplasm progression with OLARATUMAB
7.6%
of all OLARATUMAB reports
10
Deaths
8
Hospitalizations

How Dangerous Is Malignant neoplasm progression From OLARATUMAB?

Of the 43 reports, 10 (23.3%) resulted in death, 8 (18.6%) required hospitalization, and 12 (27.9%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OLARATUMAB. However, 43 reports have been filed with the FAERS database.

What Other Side Effects Does OLARATUMAB Cause?

Off label use (124) Neutropenia (66) Infusion related reaction (64) Febrile neutropenia (57) Drug ineffective (49) Death (44) Product use in unapproved indication (40) Disease progression (33) Anaphylactic reaction (29) Dyspnoea (27)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which OLARATUMAB Alternatives Have Lower Malignant neoplasm progression Risk?

OLARATUMAB vs OLECLUMAB OLARATUMAB vs OLIVE OIL\SOYBEAN OIL OLARATUMAB vs OLMESARTAN OLARATUMAB vs OLMESARTAN MEDOXOMIL OLARATUMAB vs OLMETEC

Related Pages

OLARATUMAB Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression OLARATUMAB Demographics